 1.  Short title This Act may be cited as the  Protecting Patient Access to Lifesaving COVID–19 Drugs Act of 2021 . 
 2.  Requiring group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage, without cost sharing, of certain COVID–19 antibody treatments  (a)  In general Section 6001(a) of the Families First Coronavirus Response Act ( 42 U.S.C. 1320b–5  note) is amended— (1) in the matter preceding paragraph (1), by inserting  (or, in the case of items and services described in paragraph (3), beginning on or after the date of the enactment of the Protecting Patient Access to Lifesaving COVID–19 Drugs Act of 2021)  after  this Act ; and (2)  by adding at the end the following new paragraph:  (3)  Items consisting of monoclonal antibody infusions (as specified by the Secretary) approved, cleared, or otherwise authorized by the Food and Drug Administration needed for the treatment of COVID–19 in individuals with positive COVID–19 test results, including services for the administration of such items.  .  (b)  Reimbursement for treatments Section 3202 of the CARES Act ( 42 U.S.C. 256b  note) is amended— (1) in the header, by inserting  and antibody treatments  after  testing ; (2) in subsection (a), in the matter preceding paragraph (1), by inserting  or antibody treatment, as applicable,  after  diagnostic testing ; and (3)  in subsection (b)—  (A) in the header, by inserting  and antibody treatments  after  testing ; and (B)  in paragraph (1)—  (i) by inserting  or antibody treatment  after  diagnostic test ; and (ii) by inserting  or treatment (including the administration of such treatment)  after  such test . 
